Zeposia

Bristol Myers Squibb Pharmaceuticals limited

Zeposia (ozanimod) Healthcare Professional Prescriber’s Checklist

For Healthcare Professionals

This risk minimisation material is a condition of the marketing authorisation. The Prescriber's Checklist includes information on the ozanimod treatment initiation criteria (including re-initiation); monitoring parameters prior to, during and after treatment with ozanimod, counselling points for patients and pregnancy prevention for women of childbearing potential.

---

Zeposia (ozanimod) Patient/Caregiver Guide

This risk minimisation material is a condition of the marketing authorisation. This guide should be provided to patients, or caregivers of patients, receiving treatment with ozanimod as it provides important information including what patients need to be aware of before they start taking ozanimod, the signs and symptoms of important side effects they need to look out for during treatment and how to report side effects.

---

Zeposia (ozanimod) Pregnancy-specific Patient Reminder Card

This risk minimisation material is a condition of the marketing authorisation. This card should be provided to women of childbearing potential receiving treatment with ozanimod. It contains information on the potential risks if ozanimod is used during pregnancy, how to minimise these risks through pregnancy prevention and what the patient should do if they become pregnant while on treatment with ozanimod.

---

Zessly

Sandoz Limited

Zessly Patient Alert Card

Zessly Patient Alert Card

---

Zeyzelf

Luye Pharma Limited

Rivastigmine patch (Zeyzelf) - Instructions for use and patient diary - for patients

Instructions for use and a patient diary including medication record sheets for patients that have been prescribed Zeyzelf Patch (rivastigmine transdermal system) to ensure the correct use of the patch.

---

Ziagen

ViiV Healthcare UK Ltd

Abacavir Hypersensitivity Website for Healthcare Professionals

For Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

---

Zilbrysq

UCB Pharma Limited

Zilbrysq Guide for Healthcare Professionals

For Healthcare Professionals

This guide is for healthcare professionals who will prescribe or dispense ZILBRYSQ (zilucoplan). It describes: • The potential increased risk of meningococcal infections with zilucoplan • How you can mitigate this risk by ensuring patients receive recommended meningococcal vaccinations and, if needed, antibiotic therapy • Important information for starting a patient on zilucoplan • How to counsel patients with the Patient/Carer Guide and Patient Alert Card

---

Zilbrysq Patient Alert Card

Important safety information for patients, carers and physicians

---

Zilbrysq Patient Carer Guide

This is a guide for patients who use zilucoplan and for those who care for them. It contains important safety information about the use of zilucoplan.

---

Zoledronic acid

Dr. Reddy's Laboratories (UK) Ltd

Zoledronic acid 5mg/100ml solution for infusion patient reminder card

The reminder card contains important information that you need to be aware of before and during treatment with zoledronic acid (5mg solution for infusion).

---

Ennogen Healthcare Ltd

Zoledronic acid - Patient Reminder Card

For Healthcare Professionals

This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid Ennogen 4 mg/5 ml concentrate for solution for infusion for cancer-related conditions.

---

Martindale Pharma, an Ethypharm Group Company

Zoledronic acid patient card

Zoledronic Acid Patient Card This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid (4mg/100ml solution for infusion; 4mg/5ml concentrate for solution for infusion) injections for cancer-related conditions.

---

Zoledronic Acid Patient Card

Zoledronic Acid Patient Card This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid (5mg solution for infusion).

---

Mylan

Patient Reminder Card for osteonecrosis of the jaw

Patient reminder card for osteonecrosis of the jaw before and during treatment with zoledronic acid (4mg/100ml solution for infusion; 4mg/5ml concentrate for solution for infusion) injections

---

Ranbaxy (UK) Limited a Sun Pharmaceutical Company

Doctor's information guide

For Healthcare Professionals

Doctor's information guide - Zoledronic acid 5 mg

---

Patient information guide

Patient information guide - Zoledronic acid 5 mg

---

Zoledronic Acid 5 mg solution for infusion - ONJ

Zoledronic Acid 5 mg solution for infusion - ONJ - patient reminder card

---

Seacross Pharmaceuticals Ltd

DOCTOR'S INFORMATION GUIDE

This information is part of the Risk Management Plan (RMP) for Zoledronic acid Seacross 5mg/100ml solution for infusion (hereafter refers as Zoledronic acid Seacross 5mg/100ml), and aims at minimisation of identified and potential therapy-related risks in order to optimize the benefit/risk balance. For complete information read the registered Summary of Product Characteristics of Zoledronic acid Seacross 5 mg/100ml before you prescribe Zoledronic acid Seacross 5mg/100ml.

---

ONJ-Patient Reminder Card

This reminder card containsimportant safety information that you need to be aware of before and during treatment with zoledronic acid(4mg/5ml,concentrate for solution for infusion; 4mg/100ml, solution for infusion)injections for cancer-related conditions

---

PATIENT INFORMATION GUIDE

This brochure is intended for patients with an increased risk of bone fractures that are going to be treated with Zoledronic acid Seacross 5mg/100ml solution for infusion(Hereafter refer as Zoledronic acid Seacross 5mg/100ml). Read this brochure carefully because it gives you important information about Zoledronic acid Seacross 5mg/100ml. Please also read the package leaflet ofZoledronic acid Seacross 5mg/100ml for more information.

---

PATIENT REMINDER CARD

This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid Seacross 5mg/100ml solution for infusion.

---

Tillomed Laboratories Ltd

Zoledronic Acid 4mg/5ml Concentrate for Solution for Infusion

Patient Reminder Card - Osteonecrosis of the jaw

---

Zolgensma

Novartis Pharmaceuticals UK Ltd

Zolgensma Caregiver Guide

A caregiver’s guide to Zolgensma®

---

Zolgensma Healthcare Professional Guide

For Healthcare Professionals

A healthcare professional’s guide to minimizing risks with Zolgensma

---

Zometa

Phoenix Labs

Zometa (Zoledronic Acid) Patient Reminder Card

For Healthcare Professionals

The reminder card contains important information that you need to be aware of before and during treatment with zoledronic acid (Zometa) injections.

---

Zynlonta

Swedish Orphan Biovitrum Ltd

Zynlonta - Patient Card - NP-28941

This patient alert card contains important safety information that patients need to be aware of during treatment with ZYNLONTA, including the risk of photosensitivity reactions.

---

Zypadhera

Eli Lilly and Company Limited

ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection Patient Alert Card

ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection Patient Alert Card containing important safety information for patients.

---

Neon Healthcare Ltd

Patient Alert Card

Zypadhera Patient Alert Card

---